Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma Multiforme Prior to and After Secondary Resection: an Open-Label Phase I/II Trial.

Trial Profile

Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma Multiforme Prior to and After Secondary Resection: an Open-Label Phase I/II Trial.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Sep 2011

At a glance

  • Drugs Patupilone (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Jan 2010 Planned number of patients changed from 24 to 10 as reported by ClinicalTrials.gov.
    • 22 Jan 2010 Planned end date changed from 1 Dec 2009 to 1 Dec 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top